scholarly journals Strategy of post-neoadjuvant treatment of patients with residual breast cancer

2020 ◽  
Vol 16 (1) ◽  
pp. 43-54
Author(s):  
V. V. Semiglazov ◽  
A. A. Natopkin
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Systemic Treatment ◽  
Neoadjuvant Treatment ◽  
Breast Tumors ◽  
Recurrence Risk ◽  
Molecular Profile ◽  
Malignant Breast ◽  
Selection Of ◽  
Biological Subtype

The article considers the aspects of selection of post-neoadjuvant therapy for patients with residual breast cancer depending on biological subtype and molecular profile of the tumor. Analysis of morphological and molecular markers allowing to evaluate sensitivity of malignant breast tumors with high recurrence risk to new types of systemic treatment is presented.

scholarly journals Expression analisis of the ITSN2 and TKS5 mRNA isoforms in human malignant breast tumors

2018 ◽  
Vol 16 (1) ◽  
pp. 20-27
Author(s):  
S. V. Kropyvko ◽  
L. O. Tsyba ◽  
O. V. Novokhatska ◽  
L. A. Syvak ◽  
T. Ye. Tarasenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Expression Analysis ◽  
Rna Isolation ◽  
Breast Tumors ◽  
Quantitative Real Time Pcr ◽  
Mrna Isoforms ◽  
Extensive Experience ◽  
Great Progress ◽  
Malignant Breast ◽  
The Many

Aim. Despite the great progress in cancer treating, the breast cancer remains lethal in 15 % cases. Regardless of the many years of research and extensive experience in the treatment of this type of cancer, one of the main problems in diagnosis and therapy is its high clinical and genetic heterogeneity. Thereby the identification of markers for personalized treatment of patients is still an actual issue. Methods. Collection of clinical material, RNA isolation, and expression analysis of ITSN2 and TKS5 isoforms using quantitative real time PCR with fluorescence-labeled probes. Results. We have found that ITSN2-S expression is reliably reduced in HER2/neu-positive tumors with poor prognosis. There were no significant differences in the expression of ITSN2-L and TKS5-L in the analyzed samples. Conclusions. These studies have demonstrated the possible use of ITSN2 short isoform (ITSN2-S) as a prognostic marker for breast cancer. Keywords: breast cancer, ITSN2, TKS5, expression analysis.

scholarly journals Primary breast lymphoma: a case report and review of the literature

2017 ◽  
Vol 7 (3) ◽  
Author(s):  
Kamal E.H. Mohamed ◽  
Rusha A.E. Ali
Keyword(s):  
Breast Cancer ◽  
Rare Case ◽  
Breast Tumors ◽  
Review Of The Literature ◽  
Primary Breast Lymphoma ◽  
Breast Lymphoma ◽  
First Case ◽  
High Prevalence ◽  
Malignant Breast ◽  
Hodgkin's Lymphomas

Primary breast lymphoma (PBL) represents 0.04-0.5% of all malignant breast tumors, <1% of all patients with non-Hodgkin’s lymphomas and 1.7-2.2% of all patients with extra nodal lymphomas. Despite the high prevalence of breast cancer, primary breast lymphoma is very rare. We report a rare case of PBL, successfully treated with surgery, chemotherapy and radiotherapy. This is the first case of PBL to be reported from Sudan to our knowledge.

Experience in performing organ-preserving and reconstructive plastic surgeries for malignant breast tumors at the Regional Clinical Center of Oncology in Khabarovsk

2021 ◽  
Vol 87 (1) ◽  
pp. 32-36
Author(s):  
A.A. Chernyayeva ◽  
◽  
A.S. Zenyukov ◽  
S.M. Korneyev ◽  
Ye.G. Lokalov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Local Recurrence ◽  
Clinical Oncology ◽  
Breast Tumors ◽  
Clinical Center ◽  
Malignant Breast ◽  
Oncology Center ◽  
Reconstructive Plastic

The article presents the experience of the Oncology department No. 1 of the Regional Clinical Oncology Center in Khabarovsk in performing organ-preserving and reconstructive plastic surgeries for breast cancer in the period 2014–2019. An assessment was made of the incidence of local recurrence or distant progression of the disease, as well as risk factors for their occurrence

Is Biological Subtype Prognostic of Locoregional Recurrence Risk in Women With pT1-2N0 Breast Cancer Treated With Mastectomy?

2014 ◽  
Vol 88 (1) ◽  
pp. 57-64 ◽  
Author(s):  
Pauline T. Truong ◽  
Betro T. Sadek ◽  
Maria F. Lesperance ◽  
Cheryl S. Alexander ◽  
Mina Shenouda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Locoregional Recurrence ◽  
Recurrence Risk ◽  
Biological Subtype

A Practical Clinical Approach to Adjuvant Therapy in Breast Cancer—An Update

2009 ◽  
Vol 05 (01) ◽  
pp. 49
Author(s):  
Stephanie L Hines ◽  
Winston Tan ◽  
Alvaro Moreno-Aspitia ◽  
Vivek Roy ◽  
Laura A Vallow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Adjuvant Therapy ◽  
Potential Benefit ◽  
Recurrence Risk ◽  
Clinical Approach ◽  
Her2 Positive ◽  
Heterogeneous Nature ◽  
The Individual ◽  
Disease Specific

Adjuvant therapy for breast cancer has evolved to reflect the heterogeneous nature of the disease. Specific subtypes such as luminal, HER2- positive, and basal subtypes express different molecular markers that can be targeted by a variety of novel agents; therapy is tailored to the individual profile of each tumor. New risk-stratification models, including models based on a tumor’s genetic expression, enhance assessments of recurrence risk so that the potential toxicities of a particular regimen can be weighed against the potential benefit. More precise tailoring of adjuvant therapy may be possible in the future with advances in pharmaco-genetics, which will help to predict an individual’s response to various agents. Optimal adjuvant treatment of breast cancer involves tailoring therapy to the individual patient and tumor.

Outcomes from 735 patients with breast cancer brain metastases (BM) according to biological subtype, number of BMs, and systemic treatment after local therapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 2078-2078 ◽  
Author(s):  
Anna Niwinska ◽  
Katarzyna Pogoda ◽  
Halina Rudnicka ◽  
Agnieszka Irena Jagiello-Gruszfeld ◽  
Sebastian Rybski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastasis ◽  
Brain Metastases ◽  
Systemic Treatment ◽  
Brain Lesion ◽  
Local Treatment ◽  
Local Therapy ◽  
Luminal Breast Cancer ◽  
Solitary Brain Metastasis ◽  
Biological Subtype

2078 Background: To assess survival when BM is detected according to the biological subtype of breast cancer, number of BMs and systemic treatment after local therapy. Methods: Subjects were 735 consecutive breast cancer patients with BM treated during 2003-2015. Whole brain radiotherapy was undertaken in 97%, neurosurgery -19% and systemic therapy was performed in 74% cases. The biological subtypes: triple-negative (TNBC), HER2+ER/PR-, HER2+/ER/PR+ and ER/PR+HER2- (Luminal) were determined in 714 subjects. Survival after BM detection was assessed in the entire group, in patients with a single BM (1 brain lesion regardless of metastases in other organs) and those with a solitary brain metastasis (1 brain lesion but no metastases in other organs). Factors influencing survival upon detecting BM were assessed by Cox multivariate analysis. Results: The median survivals for all patients with TNBC, HER2+ER/PR-, HER2+/ER/PR+ and Luminal breast cancer BM were respectively 4, 8, 10 and 9 months (p < 0.001). In those both treated and untreated systemically within the TNBC, HER2+ER/PR-, HER2+/ER/PR+ and Luminal subtypes survivals were correspondingly 6, 10, 14, 11 and 2, 3, 2, 2 months (p < 0.001). Median survivals of 171 patients with a single BM treated and untreated systemically were respectively 15 and 5 months (p < 0.001). Median survivals of 70 patients with solitary BM treated and untreated systemically were respectively 28 and 6 months (p < 0.001). In patients with solitary brain metastasis, median survival within the TNBC, HER2+ER/PR-, HER2+/ER/PR+ and Luminal subtypes, with systemic treatment was respectively 16, 28, 28, 28 months and without systemic treatment 6, 7, 7 and 7 months (p < 0.001). Conclusions: Patients with TNBC and BM had the worst prognosis. Systemic treatment performed after local therapy is an important factor prolonging survival of patients with breast cancer BM, even in those with solitary brain metastasis. Based on the present evidence and our recent publication, systemic treatment should be performed in all patients with BM after local treatment, even those with brain metastases as an isolated recurrence.

scholarly journals Sex Steroid Hormones in Serum and Tissue of Benign and Malignant Breast Tumor Patients

2000 ◽  
Vol 16 (3-4) ◽  
pp. 151-157 ◽  
Author(s):  
Essam A. Mady ◽  
Ezz El-Din H. Ramadan ◽  
Alaa A. Ossman
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Steroid Hormones ◽  
Breast Tumor ◽  
Tumor Tissue ◽  
Breast Tumors ◽  
Sex Steroid ◽  
Malignant Breast Tumor ◽  
Malignant Breast ◽  
Benign Breast Tumors

The ability of breast tumors to synthesize sex steroid hormones is well recognized and their local production is thought to play a role in breast cancer development and growth. The aim of this study was to estimate local intra-tumoral and circulating levels of Estrone (E1), Estrone Sulfate (E1S), Estradiol (E2), Estriol (E3), and Testosterone (T) in 33 pre- and postmenopausal women with primary breast cancer in comparison to 12 pre- and postmenopausal women with benign breast tumors. The mean levels of the studied sex hormones were higher in serum and tumor tissue of breast cancer women than those with benign breast tumors apart from Testosterone which showed a significant decrease in pre- and postmenopausal women with breast cancer (P< 0.001 for follicular phase,P< 0.001 for luteal phase, andP< 0.001 for postmenopausal). The levels of the five hormones were significantly higher intra-tumoral than in serum of both benign and malignant breast tumor women with E1S as the predominant estrogen. There was only a positive significant correlation between serum and tumor tissue levels of E1(rs= 0.52,P< 0.05 for follicular;rs= 0.63,P< 0.05 for luteal andrs= 0.58,P< 0.05 for postmenopausal) and a significant correlation between serum and tumor tissue of T (rs= 0.64,P< 0.05 for follicular;rs= -0.51,P< 0.05 for luteal andrs= -0.81,P< 0.04 for postmenopausal).

scholarly journals Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and malignant breast tumors

2019 ◽  
Author(s):  
Mustafa Fadhil ◽  
Omar Abdul- Rasheed ◽  
Manwar Al-Naqqash
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Tumor ◽  
Healthy Subjects ◽  
Breast Tumors ◽  
Breast Cancer Patients ◽  
Cancer Tumor ◽  
Malignant Breast

Background: During tumor progression, circulating monocytes and macrophages are actively recruited into tumors where they alter the tumor microenvironment to accelerate tumor progression. In response to multiple microenvironmental signals from the tumor and stromal cells, macrophages change their functional phenotypes. Based on their function, macrophages are commonly classified into both, classical M1 and alternative M2 macrophages. M2-like tumor-associated macrophages promote breast tumor growth and survival, and may migrate into the peripheral blood. However, the level of circulating M2/M1-like monocyte ratio in the peripheral blood of breast cancer patients has not been yet clarified. Aim: To compare peripheral blood M2/M1 monocyte ratio among breast cancer patients, benign breast tumor patients and healthy subjects. Also, to investigate the role of peripheral blood M2/M1 monocyte ratio as a circulating breast cancer tumor marker and to asses the validity of this marker in differentiation between benign and malignant breast tumors. Methods: Flow cytometry technique was used to determine the peripheral blood M2/M1 monocyte ratio in three groups of subjects, i.e. 45 patients with breast cancer, 40 patients with benign breast tumor, and 40 healthy subjects as a control group. The results of carbohydrate antigen15-3 (CA15-3) determination were analyzed comparatively. Results: The peripheral blood M2/M1 monocyte ratio in patients with breast cancer (0.27±0.1) was significantly higher (P<0.001) than that in healthy subjects (0.07±0.05) and than in benign tumor subjects (0.08±0.04). The area under the receiver operating characteristic (ROC) curve of peripheral blood M2/M1 monocyte ratio determination was significantly higher (P≤0.001) than that of CA15-3 levels. Conclusion: M2/M1-like monocyte ratio is of a high diagnostic value for breast cancer and is a promising differentiating marker between benign and breast cancer tumor groups.

scholarly journals Evaluation of recurrence risk after organ-sparing treatment of breast cancer depending on biological subtype of the tumor

2015 ◽  
pp. 34
Author(s):  
S. M. DEMIDOV ◽  
S. V. SAZONOV ◽  
D. A. DEMIDOV ◽  
A. Y. SUNTSOVA ◽  
T. O. IRIKH
Keyword(s):  
Breast Cancer ◽  
Recurrence Risk ◽  
Organ Sparing ◽  
Biological Subtype
Sign in / Sign up

Export Citation Format

Share Document